Homebiopharmaceutical

biopharmaceutical

ACER Down Despite FDA Nod for Urea Cycle Disorders Drug

ACER Down Despite FDA Nod for Urea Cycle Disorders Drug

December 28, 2022

Aridis Pharmaceuticals to Discuss Topline Data from Phase 3 Study of AR-301 During Corporate Update Call on January 25

Aridis Pharmaceuticals to Discuss Topline Data from Phase 3 Study of AR-301 During Corporate Update Call on January 25

December 28, 2022

Acasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia

Acasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia

December 28, 2022

Ampio Pharmaceuticals Regains Compliance with NYSE American Continued Listing Standards

Ampio Pharmaceuticals Regains Compliance with NYSE American Continued Listing Standards

December 27, 2022

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Eiger BioPharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important January 9 Deadline in Securities Class Action – EIGR

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Eiger BioPharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important January 9 Deadline in Securities Class Action – EIGR

December 27, 2022

DBV (DBVT) Up as FDA Lifts Partial Hold on Peanut Allergy Study

DBV (DBVT) Up as FDA Lifts Partial Hold on Peanut Allergy Study

December 27, 2022

Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA(TM) for Patients with Urea Cycle Disorders

Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA(TM) for Patients with Urea Cycle Disorders

December 27, 2022

Beat the Market the Zacks Way: Boeing, General Electric, AmerisourceBergen, Kimberly-Clark in Focus

Beat the Market the Zacks Way: Boeing, General Electric, AmerisourceBergen, Kimberly-Clark in Focus

December 27, 2022

Catalyst Biosciences Completes First Steps in Reverse Merger Plan

Catalyst Biosciences Completes First Steps in Reverse Merger Plan

December 27, 2022

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Eiger BioPharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – EIGR

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Eiger BioPharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – EIGR

December 24, 2022

« 1 … 5 6 7 8 9 … 558 »